Clinical trial
The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients…
NCT00001114 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00001114 |
|---|---|
| Title | The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma |
| Official title | A Randomized Phase II Trial to Determine the Safety, Tolerance, and Efficacy of Two Doses of Interferon Alfa-2b Combined With Didanosine in Patients With Kaposi's Sarcoma |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | Schering-Plough Industry Bristol-Myers Squibb |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma, Kaposi, HIV Infections |
| Intervention type | Drug |
| Interventions | Interferon alfa-2b, Didanosine |
| Enrollment | 90 |
| Completion | Mar 1, 2000 |
| First posted | Aug 31, 2001 |
| Last update posted | Nov 1, 2021 |
| Countries | Puerto Rico, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: